Results 51 to 60 of about 2,201,777 (199)

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review

Frontiers in Oncology, 2021
Introduction: Small cell lung cancer (SCLC) transformation represents a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma, which dramatically impacts patients' prognosis due to high refractoriness to conventional treatments.Case ...
Alessandro Leonetti, Roberta Minari, Giulia Mazzaschi, Letizia Gnetti, Silvia La Monica, Roberta Alfieri, Nicoletta Campanini, Michela Verzè, Andrea Olivani, Luigi Ventura, Marcello Tiseo, Marcello Tiseo   +11 more
doaj   +1 more source

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib [PDF]

, 2020
Abemaciclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6 that inhibits the transition from the G1 to the S phase of the cell cycle by blocking downstream CDK4/6-mediated phosphorylation of Rb.
Roberta Minari, Claudia Fumarola, Graziana Digiacomo, Maricla Galetti, Pier Giorgio Petronini, Marcello Tiseo, Mara Bonelli, Maicol Mancini, Silvia La Monica, Andrea Cavazzoni, Daniele Cretella, Francesco Volta, Roberta Alfieri   +12 more
core   +2 more sources

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models [PDF]

, 2022
Introduction: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients.
홍민희, 김혜련, 임선민, 표경호, 조병철, 허성구, 윤미란   +6 more
core   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling

Communications Biology, 2022
The resistance mechanism of osimertinib, a third-generation EGFR-TKI, is mediated by IL-6 and Laminin α5/FAK signaling. Ibrutinib combined with osimertinib is presented as a strategy for overcoming osimertinib acquired resistance in EGFR mutant NSCLC.
Li Li, Zhujun Li, Conghua Lu, Jianghua Li, Kejun Zhang, Caiyu Lin, Xiaolin Tang, Zhulin Liu, Yimin Zhang, Rui Han, Yubo Wang, Mingxia Feng, Yuan Zhuang, Chen Hu, Yong He   +14 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis

Frontiers in Pharmacology
BackgroundOsimertinib resistance remains a major challenge in the treatment of lung adenocarcinoma. Long non-coding RNAs (lncRNAs) have emerged as key regulators of drug resistance, but their roles in osimertinib resistance are poorly understood.
Leidi Xu, Yibo Zhang, Liangliang Xing, Ying Zhou, Ning Chang, Hangtian Xi, Xiangrui Xu, Jian Zhang, Jian Zhang   +8 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

L3MBTL1, a polycomb protein, promotes Osimertinib acquired resistance through epigenetic regulation of DNA damage response in lung adenocarcinoma

Cell Death and Disease
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) approved for patients with EGFR T790M resistance mutations as first- or second-line treatment of EGFR-positive patients.
Zihe Zhang, Yongwen Li, Ruifeng Shi, Chaoyi Jia, Songlin Xu, Guangsheng Zhu, Peijun Cao, Hua Huang, Xuanguang Li, Hongbing Zhang, Minghui Liu, Chen Chen, Hongyu Liu, Chunsheng Kang, Jun Chen   +14 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source